AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy
RH Falk, KM Alexander, R Liao, S Dorbala - Journal of the American …, 2016 - jacc.org
The amyloidoses are a group of protein-folding disorders in which≥ 1 organ is infiltrated by
proteinaceous deposits known as amyloid. The deposits are derived from 1 of several …
proteinaceous deposits known as amyloid. The deposits are derived from 1 of several …
Cancer therapy-related cardiac dysfunction: an overview for the clinician
IE Perez, S Taveras Alam… - Clinical Medicine …, 2019 - journals.sagepub.com
Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and
undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It …
undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It …
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools …
AR Lyon, S Dent, S Stanway, H Earl… - European journal of …, 2020 - Wiley Online Library
This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis
Importance Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple
myeloma can be potentially life-threatening and remain incompletely characterized. We …
myeloma can be potentially life-threatening and remain incompletely characterized. We …
[HTML][HTML] Toward a broader view of mechanisms of drug cardiotoxicity
Cardiotoxicity, defined as toxicity that affects the heart, is one of the most common adverse
drug effects. Numerous drugs have been shown to have the potential to induce lethal …
drug effects. Numerous drugs have been shown to have the potential to induce lethal …
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review
G Georgiopoulos, N Makris, A Laina, F Theodorakakou… - Cardio Oncology, 2023 - jacc.org
Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma
SPE Jayaweera… - Frontiers in …, 2021 - frontiersin.org
The proteasome is crucial for the degradation of intracellular proteins and plays an important
role in mediating a number of cell survival and progression events by controlling the levels …
role in mediating a number of cell survival and progression events by controlling the levels …
Cancer chemotherapy and cardiac arrhythmias: a review
Cardiovascular toxicity is a potential complication of cancer chemotherapy (CC) that
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …
Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1–directed novel …
Vascular cell adhesion molecule-1 (VCAM-1) has been well established as a critical
contributor to atherosclerosis and consequently as an attractive therapeutic target for anti …
contributor to atherosclerosis and consequently as an attractive therapeutic target for anti …
Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management
Abstract Purpose of Review Multiple myeloma is the second most common hematologic
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …